- Home
- IMRN vs XTLB Comparison
IMRN vs XTLB Comparison
Compare IMRN & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- XTLB
- Stock Information
- Founded
- IMRN 1994
- XTLB 1993
- Country
- IMRN Australia
- XTLB Israel
- Employees
- IMRN N/A
- XTLB N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- XTLB Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- XTLB Health Care
- Exchange
- IMRN Nasdaq
- XTLB Nasdaq
- Market Cap
- IMRN 10.1M
- XTLB 10.4M
- IPO Year
- IMRN N/A
- XTLB 2005
- Fundamental
- Price
- IMRN $1.75
- XTLB $1.24
- Analyst Decision
- IMRN Strong Buy
- XTLB
- Analyst Count
- IMRN 1
- XTLB 0
- Target Price
- IMRN $5.00
- XTLB N/A
- AVG Volume (30 Days)
- IMRN 13.7K
- XTLB 4.8K
- Earning Date
- IMRN 04-15-2025
- XTLB 05-19-2025
- Dividend Yield
- IMRN N/A
- XTLB N/A
- EPS Growth
- IMRN N/A
- XTLB N/A
- EPS
- IMRN N/A
- XTLB N/A
- Revenue
- IMRN $4,048,286.00
- XTLB $46,000.00
- Revenue This Year
- IMRN N/A
- XTLB N/A
- Revenue Next Year
- IMRN N/A
- XTLB N/A
- P/E Ratio
- IMRN N/A
- XTLB N/A
- Revenue Growth
- IMRN 82.90
- XTLB N/A
- 52 Week Low
- IMRN $1.70
- XTLB $1.09
- 52 Week High
- IMRN $3.09
- XTLB $3.48
- Technical
- Relative Strength Index (RSI)
- IMRN 41.07
- XTLB 47.54
- Support Level
- IMRN $1.73
- XTLB $1.09
- Resistance Level
- IMRN $2.09
- XTLB $1.25
- Average True Range (ATR)
- IMRN 0.14
- XTLB 0.05
- MACD
- IMRN 0.00
- XTLB 0.02
- Stochastic Oscillator
- IMRN 10.26
- XTLB 78.95
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.